INDOCO258.00

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,381 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)265.70386.26347.51347.51
Receivable Days (DSO)81.5877.2696.7696.76
Payable Days (DPO)115.62191.71264.59265.19
Cash Conversion Cycle (days)231.66271.81179.68179.08
Working Capital Turnover5.318.6113.1113.30
Asset Turnover0.850.690.710.71
Cash Conversion (CFO/Net Income)1.62-1.22-1.95-1.95
CFO/EBITDA0.640.961.361.36
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.